.Viridian Therapeutics’ phase 3 thyroid eye health condition (TED) clinical trial has hit its primary and secondary endpoints. Yet with Amgen’s Tepezza presently on the
Read moreVir increases 3 T-cell engagers from Sanofi, gives up 25% of workers
.Vir Biotechnology’s second-quarter incomes document wasn’t short of huge news. The provider welcomed a trio of clinical-stage T-cell engagers (TCEs) from Sanofi while throwing out
Read moreVertex, beaten by AATD once again, falls 2 assets on dispose of pile
.Tip’s attempt to address an unusual hereditary disease has actually reached one more drawback. The biotech tossed 2 more drug prospects onto the discard pile
Read moreVentyx’s last hope for inflamed med ends in Crohn’s failing
.Ventyx Biosciences’ Crohn’s disease medication did not assist individuals attain remission in a stage 2 trial, delivering the California biotech’s portions down over 20% at
Read moreVaxcyte rises on ‘spectacular’ 31-valent PCV gain versus Pfizer
.Vaxcyte introduced what analysts referred to as “stunning” stage 1/2 records for its 31-valent pneumococcal vaccination prospect that, if duplicated in a large pivotal research,
Read moreVaderis’ uncommon blood vessel problem medication lessens nosebleeds
.Vaderis Rehabs’ target to build the 1st medication striven specifically at a particular uncommon capillary problem came one measure nearer today along with the updates
Read moreVaccine and Keytruda combo helpful in squamous tissue cancer
.Invulnerable checkpoint inhibitors are actually the superheroes of cancer cells therapy. Medications like Bristol Myers Squibb’s Opdivo and also Merck’s Keytruda are with the absolute
Read moreVBI Vaccinations files for insolvency, seeks possession purchase
.Immunology biotech VBI Injections is diverting hazardously close to the moment of truth, with strategies to file for personal bankruptcy and sell its own assets.The
Read moreUpstream swells IPO to $255M as it details alongside CAMP4
.Upstream Bio has inflamed its own IPO to $255 thousand as the business joins CAMP4 Therapeutics this morning in coming to be the most recent
Read moreUltragenyx changes genetics treatment dosing to dial up efficiency
.A minority of patients taking Ultragenyx Pharmaceutical’s Wilson ailment gene therapy UX701 have actually come off standard-of-care medicines, leading the biotech to register a new
Read more